The at-home isolation and social distancing orders for millions of Americans is a vital element to slow to the COVID-19 pandemic. With most of our daily activities on-hold or modified for the foreseeable future, medical research is a crucial pursuit that continues despite the current environment.
Considerations for Feasibility for Translational Research For many researchers, considering the feasibility of a translational study with Sanguine Biosciences is a crucial yet challenging step. The proposed study they submit might not be possible based on real-world evidence or Sanguine’s service offerings, requiring them to modify their criteria.
The global search for a treatment targeting the novel coronavirus has led to an unlikely potential savior: a cocoa-colored llama named Winter, whose blood could hold a weapon to blunt the virus. She lives at a research farm in Belgium with about 130 other llamas and alpacas.
As a chronic autoimmune disease, patients with systemic lupus erythematosus (SLE) experience widespread inflammation and unpredictable disease flare episodes that progressively worsen over time, contributing to tissue and organ damage. Its heterogeneous nature, slow disease progression, and seemingly random symptom flares complicate research studies aimed at improving therapeutic options for SLE patients.
WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.
Antibodies in recovered victums’ blood may hold key to COVID-19 cure In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.
Hepatitis B virus (HBV) is the world’s most common cause of chronic viral infection. Individuals may become infected through contact with bodily fluids or from mother to child during birth. Some people with acute HBV infections experience symptoms like vomiting, yellowish skin, dark urine, fatigue, and abdominal pain, while others feel no symptoms at all.
The broad spectrum of clinical manifestations seen in systemic lupus erythematosus (SLE) makes it challenging to characterize the disease meaningfully. Particularly problematic for researchers and physicians alike is the apparent classification of differences between acute episodes and chronic disease damage. To that end, the SLE disease activity index (SLEDAI-2K) functions to standardize the assessment of disease severity by clinicians globally.
Phlebotomist Teams Assisting Researchers in Select Cities Transcript: Trace Gallagher: Well, phlebotomists just may be the unsung heroes in the fight against COVID-19. Teams of licensed phlebotomists in select cities are suiting up in protective gear and masks and heading into homes of former coronavirus patients.